Last updated on June 2019

Trial of H3B-6545 in Women With Locally Advanced or Metastatic Estrogen Receptor-positive HER2 Negative Breast Cancer

Brief description of study

The purpose of phase 1 is to determine safety, tolerability and pharmacokinetics (PK) of H3B-6545 in women with locally advanced or metastatic estrogen receptor-positive, human epidermal growth factor 2 (HER2)-negative breast cancer.

The purpose of phase 2 is to estimate the efficacy of H3B-6545 in terms of response rate, duration of response (DoR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).

Clinical Study Identifier: NCT03250676

Find a site near you

Start Over

Holy Cross Hospital Inc

Fort Lauderdale, FL United States
  Connect »

Florida Cancer Specialists North

Saint Petersburg, FL United States
  Connect »

Carle Cancer Center

Urbana, IL United States
  Connect »

University of Michigan

Ann Arbor, MI United States
  Connect »

Saint Luke's Cancer Institute

Kansas City, MO United States
  Connect »

Research Medical Center

Kansas City, MO United States
  Connect »

University of North Carolina

Chapel Hill, NC United States
  Connect »

Tennessee Oncology

Nashville, TN United States
  Connect »

Velindre Cancer Centre

Cardiff, United Kingdom
  Connect »

Barts Health NHS Trust

London, United Kingdom
  Connect »

Christie Hospital

Manchester, United Kingdom
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.